Substance Use Disorder Treatment: Opportunities for Interdisciplinary Collaboration in Neurology and Beyond

Abstract

Driving the overdose epidemic, a significant proportion of adult and adolescent patients seen in neurology practice and hospital settings has substance use disorder. Fortunately, there are effective treatments available, in particular for opioid addiction. Some elements of treatment can be delivered directly in medical office-based settings, while others are best provided from within specialized addiction treatment facilities. In this article, we review the nature of substance use disorders, and the various treatment approaches that can be utilized to stabilize patients and facilitate their building a strong recovery foundation. Some interventions discussed may be directly provided by a physician identifying the disorder, while others involve collaboration with specialized addiction treatment centers and recovery support entities.

Keywords

Substance use disorder - addiction - overdose - collaborative care - opioid treatment program - methadone - buprenorphine

Publikationsverlauf

Artikel online veröffentlicht:
18. Juni 2024

• References

• 1 Center for Disease Control and Prevention. National Center for Health Statistics, Multiple Cause of Death 1999–2021 on CDC WONDER online database, released 1/2023. Accessed May 23, 2024 at: Wonder.cdc.gov.
• 2 Brooner RK, Kidorf MS, King VL. et al. Managing psychiatric comorbidity within versus outside of methadone treatment settings: a randomized and controlled evaluation. Addiction 2013; 108 (11) 1942-1951
• 3 Clark MR, Stoller KB, Brooner RK. Assessment and management of chronic pain in individuals seeking treatment for opioid dependence disorder. Can J Psychiatry 2008; 53 (08) 496-508
• 4 Dunn KE, Brooner RK, Clark MR. Severity and interference of chronic pain in methadone-maintained outpatients. Pain Med 2014; 15 (09) 1540-1548
• 5 NIDA (National Institute on Drug Abuse). 2021, April 13. Why is there comorbidity between substance use disorders and mental illnesses? Accessed November 1, 2023 at: https://nida.nih.gov/publications/research-reports/common-comorbidities-substance-use-disorders/why-there-comorbidity-between-substance-use-disorders-mental-illnesses
• 6 SAMHSA (Substance Abuse and Mental Health Services Administration). Substance Use Disorder Treatment for People With Co-Occurring Disorders. Treatment Improvement Protocol (TIP) Series, No. 42. SAMHSA Publication No. PEP20–02–01–004. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2020
• 7 Davidson L, Rowe M, DiLeo P, Bellamy C, Delphin-Rittmon M. Recovery-oriented systems of care: a perspective on the past, present, and future. Alcohol Res 2021; 41 (01) 09
• 8 McKendrick G, Stull SW, Sharma A, Dunn KE. Availability and Opportunities for Expansion of Buprenorphine for the Treatment of Opioid Use Disorder. Semin Neurol 2024(ahead of publication)
• 9 Madras BK, Ahmad NJ, Wen J, Sharfstein JS. Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers within the Treatment System. NAM Perspect 2020;2020;
• 10 Brooner RK, Kidorf MS, King VL. et al. Behavioral contingencies improve counseling attendance in an adaptive treatment model. J Subst Abuse Treat 2004; 27 (03) 223-232
• 11 Brooner RK, Kidorf MS, King VL, Stoller KB, Neufeld KJ, Kolodner K. Comparing adaptive stepped care and monetary-based voucher interventions for opioid dependence. Drug Alcohol Depend 2007; 88 (Suppl. 02) S14-S23
• 12 SAMHSA (Substance Abuse and Mental Health Services Administration). Federal Guidelines for Opioid Treatment Programs. HHS Publication No. (SMA) XX–XXXX. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015
• 13 Stack E, Hildebran C, Leichtling G. et al. Peer recovery support services across the continuum: in community, hospital, corrections, and treatment and recovery agency settings - a narrative review. J Addict Med 2022; 16 (01) 93-100
• 14 Fridell M, Bäckström M, Hesse M, Krantz P, Perrin S, Nyhlén A. Prediction of psychiatric comorbidity on premature death in a cohort of patients with substance use disorders: a 42-year follow-up. BMC Psychiatry 2019; 19 (01) 150
• 15 Padwa H, Urada D, Antonini VP, Ober A, Crèvecoeur-MacPhail DA, Rawson RA. Integrating substance use disorder services with primary care: the experience in California. J Psychoactive Drugs 2012; 44 (04) 299-306
• 16 Hill K, Kuo I, Shenoi SV, Desruisseaux MS, Springer SA. Integrated care models: HIV and substance use. Curr HIV/AIDS Rep 2023; 20 (05) 286-295
• 17 Lucas GM, Mullen BA, McCaul ME, Weidle PJ, Hader S, Moore RD. Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy. AIDS Patient Care STDS 2007; 21 (08) 564-574
• 18 Maryland Department of Health, Maryland Medicaid Administration. Maryland Chronic Health Homes. Accessed November 1, 2023 at: https://health.maryland.gov/mmcp/pages/health-homes.aspx
• 19 Stoller K, Fagan P, Dunbar L. et al. Integrative care management for substance abusing Medicaid recipients. Paper presented at: College for Problems of Drug Dependence Annual Scientific Meeting, Quebec City, Quebec; 2007
• 20 Sigmon SC. The untapped potential of office-based buprenorphine treatment. JAMA Psychiatry 2015; 72 (04) 395-396
• 21 Kim J, Lesko CR, Fojo AT. et al. The effect of buprenorphine on human immunodeficiency virus viral suppression. Clin Infect Dis 2021; 73 (11) 1951-1956
• 22 Falade-Nwulia O, Agee T, Kelly SM. et al. Implementing a peer-supported, integrated strategy for substance use disorder care in an outpatient infectious disease clinic is associated with improved patient outcomes. Int J Drug Policy 2023; 121: 104191
• 23 Fingerhood MI, King VL, Brooner RK, Rastegar DA. A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment. Subst Abus 2014; 35 (02) 122-126
• 24 Sweeney MM, Prichett L, Fingerhood MI. et al. Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting. Am J Addict 2022; 31 (03) 256-260
• 25 Krawczyk N, Rivera BD, Jent V, Keyes KM, Jones CM, Cerdá M. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019". Int J Drug Policy 2022; 110: 103786
• 26 Cabreros I, Griffin BA, Saloner B, Gordon AJ, Kerber R, Stein BD. Buprenorphine prescriber monthly patient caseloads: an examination of 6-year trajectories. Drug Alcohol Depend 2021; 228: 109089
• 27 Stoller KB. A collaborative opioid prescribing (CoOP) model linking opioid treatment programs with office-based buprenorphine providers. Addict Sci Clin Pract 2015; 10 (Suppl. 01) A63
• 28 Stoller KB, Stephens MC, Schorr A. Integrated service delivery models for opioid treatment programs in an era of increasing opioid addiction, health reform, and parity. American Association for the Treatment of Opioid Dependence. Commissioned by Substance Abuse and Mental Health Administration. Accessed May 23, 2024 at: https://www.aatod.org/wp-content/uploads/2024/02/Integrated-Service-Delivery-Models.pdf
• 29 Brooklyn JR, Sigmon SC. Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact. J Addict Med 2017; 11 (04) 286-292